

Annex A – Tables and Figure

Table 1. Indications of the different treatments in each country

Treatment group	Indication Spain	Indication France ^l	Indication Norway	Indication Germany	Indication United Kingdom
Plain codeine	Respiratory (89.5%), Pain (2.3%), Unknown (7.8%), Digestive (0.3%)	Cough only Marketing cessation in 2013 for last medicine with pain indication	Pain only	GPs: Cough (71%), Pain (7%), Unknown (21%) Paediatricians: Cough (78%), Pain (2%), Unknown (19%)	Cough
Codeine + NSAID	Respiratory (83%), Unknown (9.6%), Pain (6.4%), Digestive (1.0%)	Pain only	Pain only	GPs: Pain (52%), Cough (31%), Unknown (17%) Paediatricians: Pain (66%), Cough (8%), Unknown (27%)	Acute moderate pain
Codeine + sympathomimetic or expectorant		Cough only	(Not marketed in NO)	Cough	Cough
Tramadol	Pain (100%)	Pain	Pain	Pain	Pain
Dihydrocodeine	Respiratory (100%)	Pain	Pain	GPs: Cough (78%), Pain (5%), Unknown (18%), Paediatricians: Cough (60%), Pain (3%), Unknown (37%)	Pain
Hydromorphone	Pain musculoskeletal (89%), Pain other (11%)	Pain	Pain	Pain	Pain
Ibuprofen	Respiratory (74%), Pain musculoskeletal (20%), Pain other (6%)	Pain and/or fever	Pain	GPs: Pain (40%), Fever (8%), Unknown (52%) Paediatricians: Pain (24%), Fever (18%), Unknown (58%)	Pain, Fever, Other
Morphine	Pain other (85%), Pain musculoskeletal (15%)	Pain	Pain	Pain	Pain
Oxycodone	Pain musculoskeletal (95%), Pain other (5%),	Pain	Pain	Pain	Pain
Tilidine/naloxone	NA*	Not marketed or not reimbursed	NA ^{II}	Pain	Not marketed
Metamizole	Pain musculoskeletal (70%), Pain other (30%)	Not marketed or not reimbursed		GPs: Pain (61%), Fever (1%), Unknown (38%) Paediatricians: Pain (58%), Fever (6%), Unknown (36%)	Not marketed



Treatment group	Indication Spain	Indication France [†]	Indication Norway	Indication Germany	Indication United Kingdom
Dextromethorphan and ethylmorphine	Respiratory (100%)	Not marketed or not reimbursed	Cough only [¶]		

* Tilidine/naloxone and ethylmorphine containing medicines are not available in Spain.

† based on indications of these drugs in their Marketing Authorisation during the period of interest.

¶ Tilidine is not marketed in Norway and metamizole only for veterinarian use.

||| Dextromethorphan is not marketed in Norway.

Table 2 - List of treatment groups/sub-groups included in the analysis including the breakdown of exposure data by sub-group in France, Norway, Germany, Spain and United Kingdom

Treatment group		Treatment sub-group	n Prescriptions	Within treatment group proportion (%)
1. Codeine-containing products	1.1 Plain codeine	1 011 404	32,94	
	1.2 Codeine in combination with an analgesic or NSAID*	1 341 331	43,69	
	1.3 Codeine in combination with a sympathomimetic or expectorant	572 413	18,64	
	1.4. Codeine in all other combinations (except opium)	144 941	4,72	
2. Opioid antitussives, excluding codeine	2.1. Dextromethorphan, incl. combinations with other agents	4 475 212	38,00	
	2.2 Ethylmorphine, incl. combinations with other agents	7436	0,06	
	2.3 Pholcodine, incl. combinations with other agents	7 293 138	61,93	
	2.4 Dihydrocodeine, incl. combinations where indicated for cough	-	-	
	2.5. Opium derivatives and expectorants	-	-	
3. Opioid analgesics, excluding codeine	3.1 Hydromorphone, incl. combination with non-opioids	124	0,01	
	3.2 Morphine (incl. opium), incl. combination with non-opioids	315674	20,58	
	3.3 Oxycodone, incl. combination with non-opioids	5366	0,35	
	3.4 Tilidine/naloxone, incl. combination with non-opioids	-	-	
	3.5 Tramadol, incl. combination with non-opioids	1 199 599	78,21	
	3.6 Dihydrocodeine, incl. combination with non-opioids	1347	0,09	
	3.7 Buprenorphine, incl. combination preparations	7642	0,50	
	3.8 Diamorphine	-	-	
	3.9 Fentanyl, transdermal, buccal or nasal administration only	4139	0,27	
4. Non-opioid analgesics	4.1 Metamizole, incl. combination with other non-opioid analgesics*	-	-	
	4.2 Prescribed non-topical ibuprofen, incl. combination with other non-opioid analgesics except metamizole*	27 869 776	15,68	
	4.3 Prescribed paracetamol, incl. combination with other non-opioid analgesics except metamizole and ibuprofen*	149 841 789	84,32	
5. Non-opioid antitussives	5.1 Simple linctus, incl. simple linctus paediatric	-	-	
	5.2 Other non-opioid antitussives	17 267 047	100,00	

Norway

Treatment group	Treatment sub-group	n Prescriptions	Within treatment group proportion (%)
1. Codeine-containing products	1.1 Plain codeine	1726	2.40
	1.2 Codeine in combination with an analgesic or NSAID*	71 084	97.60
	1.3 Codeine in combination with a sympathomimetic or expectorant	-	-
	1.4. Codeine in all other combinations (except opium)	-	-
2. Opioid antitussives, excluding codeine	2.1. Dextromethorphan, incl. combinations with other agents	-	-
	2.2 Ethylmorphine, incl. combinations with other agents	222 639	85.40
	2.3 Pholcodine, incl. combinations with other agents	-	-
	2.4 Dihydrocodeine, incl. combinations where indicated for cough	-	-
	2.5. Opium derivatives and expectorants	37 990	14.60
3. Opioid analgesics, excluding codeine	3.1 Hydromorphone, incl. combination with non-opioids	-	-
	3.2 Morphine (incl. opium), incl. combination with non-opioids	901	4.70
	3.3 Oxycodone, incl. combination with non-opioids	1861	9.80
	3.4 Tilidine/naloxone, incl. combination with non-opioids	-	-
	3.5 Tramadol, incl. combination with non-opioids	15 836	84.50
	3.6 Dihydrocodeine, incl. combination with non-opioids	-	-
	3.7 Buprenorphine, incl. combination preparations	245	1.30
	3.8 Diamorphine	-	-
	3.9 Fentanyl, transdermal, buccal or nasal administration only	137	0.70
4. Non-opioid analgesics	4.1 Metamizole, incl. combination with other non-opioid analgesics*	-	-
	4.2 Prescribed non-topical ibuprofen, incl. combination with other non-opioid analgesics except metamizole*	84 587	56.80
	4.3 Prescribed paracetamol, incl. combination with other non-opioid analgesics except metamizole and ibuprofen*	64 361	43.20
5. Non-opioid antitussives	5.1 Simple linctus, incl. simple linctus paediatric	-	-
	5.2 Other non-opioid antitussives	-	-

Germany

Treatment group	Treatment sub-group	n Prescriptions	Within treatment group proportion (%)
1. Codeine-containing products	1.1 Plain codeine	61 966	91.84
	1.2 Codeine in combination with an analgesic or NSAID*	5412	8.02
	1.3 Codeine in combination with a sympathomimetic or expectorant	97	0.14
	1.4. Codeine in all other combinations (except opium)	0	
2. Opioid antitussives, excluding codeine	2.1. Dextromethorphan, incl. combinations with other agents	25 863	43.42
	2.2 Ethylmorphine, incl. combinations with other agents	0	
	2.3 Pholcodine, incl. combinations with other agents	0	
	2.4 Dihydrocodeine, incl. combinations where indicated for cough	33 702	56.58
	2.5. Opium derivatives and expectorants	0	
3. Opioid analgesics, excluding codeine	3.1 Hydromorphone, incl. combination with non-opioids	50	1.28
	3.2 Morphine (incl. opium), incl. combination with non-opioids	952	24.38
	3.3 Oxycodone, incl. combination with non-opioids	160	4.10
	3.4 Tilidine/naloxone, incl. combination with non-opioids	327	8.37
	3.5 Tramadol, incl. combination with non-opioids	2166	55.47
	3.6 Dihydrocodeine, incl. combination with non-opioids	0	
	3.7 Buprenorphine, incl. combination preparations	133	3.41
	3.8 Diamorphine	0	
	3.9 Fentanyl, transdermal, buccal or nasal administration only	117	3.00
4. Non-opioid analgesics	4.1 Metamizole, incl. combination with other non-opioid analgesics*	54 555	1.41
	4.2 Prescribed non-topical ibuprofen, incl. combination with other non-opioid analgesics except metamizole*	2 530 754	65.33
	4.3 Prescribed paracetamol, incl. combination with other non-opioid analgesics except metamizole and ibuprofen*	1 288 643	33.26
5. Non-opioid antitussives	5.1 Simple linctus, incl. simple linctus paediatric	3 427 154	100.00
	5.2 Other non-opioid antitussives		

Spain

Treatment group	Treatment sub-group	n Prescriptions	Within treatment group proportion (%)
1. Codeine-containing products	1.1 Plain codeine	109 157	41.86
	1.2 Codeine in combination with an analgesic or NSAID*	151 533	58.11
	1.3 Codeine in combination with a sympathomimetic or expectorant	101	0.04
	1.4. Codeine in all other combinations (except opium)	0	0
2. Opioid antitussives, excluding codeine	2.1. Dextromethorphan, incl. combinations with other agents	146 389	93.91
	2.2 Ethylmorphine, incl. combinations with other agents	0	0
	2.3 Pholcodine, incl. combinations with other agents	0	0
	2.4 Dihydrocodeine, incl. combinations where indicated for cough	9495	6.10
3. Opioid analgesics, excluding codeine	3.1 Hydromorphone, incl. combination with non-opioids	10	0.16
	3.2 Morphine (incl. opium), incl. combination with non-opioids	152	2.45
	3.3 Oxycodone, incl. combination with non-opioids	69	1.11
	3.4 Tilidine/naloxone, incl. combination with non-opioids	0	0
	3.5 Tramadol, incl. combination with non-opioids	5722	92.17
	3.6 Dihydrocodeine, incl. combination with non-opioids	0	0
	3.7 Buprenorphine, incl. combination preparations	18	0.29
	3.8 Diamorphine	0	0
	3.9 Fentanyl, transdermal, buccal or nasal administration only	237	3.82
4. Non-opioid analgesics	4.1 Metamizole, incl. combination with other non-opioid analgesics*	152 549	1.82
	4.2 Prescribed non-topical ibuprofen, incl. combination with other non-opioid analgesics except metamizole*	5 142 788	61.45
	4.3 Prescribed paracetamol, incl. combination with other non-opioid analgesics except metamizole and ibuprofen*	3 073 384	36.72
5. Non-opioid antitussives	5.1 Simple linctus, incl. simple linctus paediatric	0	0
	5.2 Other non-opioid antitussives	50 6263	100

United Kingdom

Treatment group	Treatment sub-group	<i>n</i> Prescriptions	Within treatment group proportion (%)
1. Codeine-containing products	1.1 Plain codeine	29 073	25.10
	1.2 Codeine in combination with an analgesic or NSAID*	86 768	74.90
	1.3 Codeine in combination with a sympathomimetic or expectorant	5	0.0
	1.4. Codeine in all other combinations (except opium)	-	-
2. Opioid antitussives, excluding codeine	2.1. Dextromethorphan, incl. combinations with other agents	184	0.4
	2.2 Ethylmorphine, incl. combinations with other agents	-	-
	2.3 Pholcodine, incl. combinations with other agents	42 223	99.60
	2.4 Dihydrocodeine, incl. combinations where indicated for cough	-	-
3. Opioid analgesics, excluding codeine	3.1 Hydromorphone, incl. combination with non-opioids	-	-
	3.2 Morphine (incl. opium), incl. combination with non-opioids	5 073	18.70
	3.3 Oxycodone, incl. combination with non-opioids	851	3.10
	3.4 Tilidine/naloxone, incl. combination with non-opioids	-	-
	3.5 Tramadol, incl. combination with non-opioids	7 587	28.00
	3.6 Dihydrocodeine, incl. combination with non-opioids	11 356	41.90
	3.7 Buprenorphine, incl. combination preparations	781	2.90
	3.8 Diamorphine	258	1.00
	3.9 Fentanyl, transdermal, buccal or nasal administration only	1 204	4.40
4. Non-opioid analgesics	4.1 Metamizole, incl. combination with other non-opioid analgesics*	-	-
	4.2 Prescribed non-topical ibuprofen, incl. combination with other non-opioid analgesics except metamizole*	729 036	31.00
	4.3 Prescribed paracetamol, incl. combination with other non-opioid analgesics except metamizole and ibuprofen*	1 620 364	69.00
5. Non-opioid antitussives	5.1 Simple linctus, incl. simple linctus paediatric	117 691	100.00
	5.2 Other non-opioid antitussives	-	-

Table 3. Number of children below 18 years of age per treatment group by quarter in France, Norway, Germany, Spain and United Kingdom, between 2010-2017

Year / Quarter	France					Total population N < 18 YOA in person years
	Treatment groups					
	Codeine-Containing products	Opioid antitussive, excluding codeine	Opioid analgesics, excluding codeine	Non-opioid analgesics	Non-opioid antitussives	
2010Q1	116140	382151	31594	4075485	875570	3216071
2010Q2	110534	256716	31239	3632020	477317	3251805
2010Q3	89157	208296	26475	3183378	307940	3287539
2010Q4	127324	480520	31206	4357604	634176	3287539
2011Q1	147803	642917	34817	5080346	721702	3233738
2011Q2	120834	233582	36464	3655109	331552	3269668
2011Q3	97203	196604	30027	3219275	307773	3305599
2011Q4	151025	451415	36317	4452653	657350	3305599
2012Q1	152785	468495	35161	4617349	629712	3247921
2012Q2	128835	238414	33726	3646856	354147	3247921
2012Q3	109995	188994	29220	3223576	290738	3283612
2012Q4	167655	439646	35693	4549315	642349	3283612
2013Q1	170982	598476	34785	5158272	761379	3232418
2013Q2	124475	259758	36330	3670511	378277	3268333
2013Q3	77681	190561	35408	3365664	294624	3304249
2013Q4	83024	390597	46160	4313989	581673	3304249
2014Q1	84389	447928	49193	4500505	592974	3245798
2014Q2	59823	229082	50627	3599573	334760	3281862
2014Q3	49792	184881	44481	3211407	282220	3317927
2014Q4	70736	431670	54150	4362999	620862	3317927
2015Q1	85468	612673	52703	5010752	766621	3261978
2015Q2	52329	219073	52740	3484201	325078	3298223
2015Q3	47094	211265	47302	3361030	327446	3334467
2015Q4	60980	396091	57272	4281518	584485	3334467
2016Q1	71327	586145	58110	5128836	776400	3310763
2016Q2	49787	237423	58529	3672844	351106	3310763
2016Q3	40519	166794	50232	3147382	260949	3347145
2016Q4	61511	453286	58988	4448987	645235	3347145
2017Q1	63875	435728	60170	4419671	577363	3294805
2017Q2	44782	166096	60304	3327569	257673	3331414
2017Q3	40803	197668	51071	3217102	315314	3368023
2017Q4	52263	393337	58328	4272397	619632	3368023

Norway						
Year / Quarter	Treatment groups					Total population N < 18 YOA in person years
	Codeine-Containing products	Opioid antitussive, excluding codeine	Opioid analgesics, excluding codeine	Non-opioid analgesics	Non-opioid antitussives	
2010Q1	2287	10233	239	3399	NR	4498243
2010Q2	2185	6165	248	3251	NR	4448812
2010Q3	1850	4914	250	3066	NR	4400455
2010Q4	2553	12265	321	3851	NR	4400455
2011Q1	2391	13117	318	3930	NR	4519405
2011Q2	2268	5535	279	3250	NR	4469741
2011Q3	2115	5978	299	3095	NR	4421157
2011Q4	2723	17056	378	4212	NR	4421157
2012Q1	2650	15547	349	4184	NR	4547448
2012Q2	2415	5754	360	3435	NR	4497476
2012Q3	2076	4282	363	3205	NR	4448590
2012Q4	2818	9645	473	4181	NR	4448590
2013Q1	2446	12563	377	3913	NR	4553971
2013Q2	2448	4998	396	3551	NR	4503927
2013Q3	1940	3479	381	3317	NR	4454971
2013Q4	2465	6717	500	4485	NR	4454971
2014Q1	1888	8161	408	4257	NR	4563152
2014Q2	1824	4974	522	4218	NR	4513008
2014Q3	1458	4175	449	3726	NR	4463953
2014Q4	1846	9873	607	4957	NR	4463953
2015Q1	1480	11233	493	4627	NR	4564949
2015Q2	1412	4539	585	4061	NR	4514785
2015Q3	1248	3311	505	3655	NR	4465711
2015Q4	1657	8443	692	4830	NR	4465711
2016Q1	1345	9854	500	4784	NR	4584768
2016Q2	1424	4846	657	4666	NR	4534386
2016Q3	1195	4946	576	4101	NR	4485099
2016Q4	1610	11164	716	5533	NR	4485099
2017Q1	1272	10108	589	5442	NR	4587040
2017Q2	1265	5709	652	4821	NR	4536633
2017Q3	1140	4503	606	4665	NR	4487321
2017Q4	1537	9370	830	6231	NR	4487321

Year / Quarter		Treatment groups				Total population N < 18 YOA in person years
		Codeine-Containing products	Opioid antitussive, excluding codeine	Opioid analgesics, excluding codeine	Non-opioid analgesics	Non-opioid antitussives
2010Q1	2604	1792	997	62998	71348	108475
2010Q2	1554	1371	616	49854	44820	113239
2010Q3	1288	1024	485	51134	39136	117072
2010Q4	3312	2070	1243	78619	87728	125051
2011Q1	4147	2157	1650	102386	98590	125835
2011Q2	1517	879	575	59533	45448	132362
2011Q3	1448	874	679	67122	50608	138604
2011Q4	4156	2116	1469	90982	99720	145600
2012Q1	3852	2022	1517	98271	96839	142795
2012Q2	1859	952	770	69932	54059	146809
2012Q3	1453	712	668	70498	47192	153725
2012Q4	3131	1613	1201	97521	95149	161079
2013Q1	5864	2543	2513	148427	136239	157873
2013Q2	1903	912	910	85932	65440	166524
2013Q3	1470	269	707	88857	55688	173808
2013Q4	2966	239	1125	102871	93955	179129
2014Q1	3803	147	1425	118218	109553	172215
2014Q2	1748	95	764	88971	62226	177567
2014Q3	1308	73	677	89775	53830	183484
2014Q4	2673	123	1584	117842	107914	188161
2015Q1	3555	206	2543	152759	133355	179367
2015Q2	884	55	728	88343	59544	183732
2015Q3	603	69	552	94829	54587	188288
2015Q4	769	131	1009	118878	99301	191701
2016Q1	965	202	1511	157899	127706	184028
2016Q2	468	95	700	100640	60872	184895
2016Q3	382	87	507	96764	51562	187677
2016Q4	881	199	1130	127806	106893	188387
2017Q1	1037	239	1409	145368	120851	176449
2017Q2	390	83	531	91980	54302	177163
2017Q3	358	78	534	95987	55291	177610
2017Q4	683	163	850	115286	90437	176126

Spain						
Year / Quarter	Treatment groups					Total population N < 18 YOA in person years
	Codeine-Containing products	Opioid antitussive, excluding codeine	Opioid analgesics, excluding codeine	Non-opioid analgesics	Non-opioid antitussives	
2010Q1	14197	14012	125	177789	44064	247655
2010Q2	9902	9858	147	163865	32829	254214
2010Q3	5262	6106	103	124272	18802	258970
2010Q4	14346	15615	124	190345	48171	261432
2011Q1	21604	17454	129	246338	61519	259216
2011Q2	9206	8684	136	172080	30296	262872
2011Q3	4883	5692	109	132504	19100	267199
2011Q4	12906	15637	127	199139	48226	267969
2012Q1	20535	16778	172	275520	62676	317270
2012Q2	8121	8181	153	204067	29284	326986
2012Q3	3239	2679	123	144953	8012	335766
2012Q4	6942	2047	159	220527	3483	339725
2013Q1	8712	1641	145	275398	3839	335169
2013Q2	4635	980	171	202161	2776	340271
2013Q3	2501	472	132	156049	1589	344869
2013Q4	6302	1253	177	223851	3703	345437
2014Q1	8803	1427	189	255563	4183	331333
2014Q2	3599	1076	171	198336	2886	335608
2014Q3	2585	782	127	143443	1931	340329
2014Q4	6851	2007	168	218316	5053	341100
2015Q1	12422	2529	181	283517	6560	332150
2015Q2	3382	1017	147	180132	2664	335806
2015Q3	2897	674	135	143007	1656	339136
2015Q4	6068	1752	202	206736	3866	339509
2016Q1	9418	2168	178	260839	4791	332647
2016Q2	4525	1119	178	203727	2633	330877
2016Q3	2747	602	141	141387	1414	333708
2016Q4	7772	1632	161	217023	3680	333971
2017Q1	8755	1677	223	231195	4036	320316
2017Q2	3186	900	220	176220	2051	323677
2017Q3	3320	675	162	143690	1530	327006
2017Q4	7295	1383	179	211049	3364	326748

United Kingdom						
Year / Quarter	Treatment groups					Total population N < 18 YOA in person years
	Codeine-Containing products	Opioid antitussive, excluding codeine	Opioid analgesics, excluding codeine	Non-opioid analgesics	Non-opioid antitussives	
2010Q1	3041	1457	477	55752	3540	274994
2010Q2	2689	859	441	46907	2309	279825
2010Q3	1882	554	307	37481	1595	270846
2010Q4	2590	1759	377	63346	5657	275384
2011Q1	2958	1370	448	58414	4283	273738
2011Q2	2585	637	482	42694	2267	280788
2011Q3	1995	515	320	36250	1766	272755
2011Q4	2325	1300	368	52345	4711	276142
2012Q1	2951	1294	462	57969	4462	278552
2012Q2	2534	702	464	43100	2478	281975
2012Q3	1892	494	303	33987	1743	273810
2012Q4	2404	1049	375	52973	4543	275804
2013Q1	2585	854	423	49577	3398	272334
2013Q2	2432	439	444	37405	2093	276374
2013Q3	1661	233	298	29306	1356	265903
2013Q4	1974	501	352	41454	3351	261779
2014Q1	2309	509	388	41513	2880	257708
2014Q2	2066	310	414	32465	1810	261429
2014Q3	1505	200	275	24304	1088	247194
2014Q4	1853	560	323	39160	3311	242228
2015Q1	2113	458	361	36503	2472	232309
2015Q2	1663	216	315	25026	1263	228964
2015Q3	1174	135	287	21357	943	217229
2015Q4	1383	327	310	29038	2344	206177
2016Q1	1633	369	321	27880	1627	199719
2016Q2	1417	179	332	19841	958	197798
2016Q3	851	130	216	14264	626	183491
2016Q4	1093	278	229	19918	1765	182071
2017Q1	1248	216	243	17691	1144	175269
2017Q2	1072	97	232	12418	541	174500
2017Q3	741	63	159	10100	515	165632
2017Q4	896	133	192	14390	1226	162633

Figure section 6.3 - Prevalence of use of codeine and alternative medicines (patient level) for all children 0-17 years of age, in Spain, 2010-2017

